# DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)

Source: https://onco.cc/terms/dipss-mipss70/  
OnCo record `dipss-mipss70` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Myelofibrosis risk scores decide the biggest question in the disease, whether to go for a stem-cell transplant: DIPSS uses age, blood counts, blasts and symptoms, DIPSS-plus adds chromosomes, transfusions and platelets, and MIPSS70 adds the mutations that mark a dangerous clone.

## Summary

What is measured: expected survival in primary myelofibrosis, and so the case for a transplant. How: IPSS (2009, at diagnosis) and DIPSS (dynamic, at any time) score age over 65, haemoglobin under 100 g/L, white cells over 25, circulating blasts of 1 percent or more and constitutional symptoms; DIPSS-plus adds an unfavourable karyotype, platelets under 100 and transfusion dependence, giving low, intermediate-1, intermediate-2 and high risk with median survivals of about 15, 6.5, 3 and 1.3 years. MIPSS70, for transplant-age patients, adds high-molecular-risk mutations (ASXL1, SRSF2, EZH2, IDH1, IDH2, U2AF1 Q157), the absence of a type 1 CALR mutation, two or more such mutations and marrow fibrosis grade 2 or more; MIPSS70-plus version 2 adds a very-high-risk karyotype and sex-adjusted haemoglobin; GIPSS is genetics only, and MYSEC-PM serves myelofibrosis after polycythaemia vera or essential thrombocythaemia. Inputs: blood count and film, marrow biopsy with fibrosis grade, karyotype and a myeloid sequencing panel. What a result changes: intermediate-2 or high risk in a fit patient is the indication for allogeneic transplant, the only cure; lower-risk disease is watched or treated for symptoms and spleen with JAK inhibitors (ruxolitinib, fedratinib, pacritinib when platelets are low, momelotinib when anaemic); the scores set trial entry. Where it matters: primary myelofibrosis.

## Fields

- Kind: Term
- Last checked: 2026-09-17
- Also known as: DIPSS; DIPSS-plus; IPSS for myelofibrosis; MIPSS70; MIPSS70-plus; MIPSS70+ v2; MIPSS70-plus version 2; GIPSS; MYSEC-PM; high-molecular-risk mutations; HMR mutations; myelofibrosis risk score; intermediate-2 myelofibrosis; high-risk myelofibrosis

## Connected records

- terms: [Allogeneic stem cell transplant (allo-SCT)](https://onco.cc/terms/allogeneic-transplant/), [Blasts (leukaemic blast cells)](https://onco.cc/terms/blasts/), [Cytogenetics and karyotype](https://onco.cc/terms/cytogenetics/), [MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden](https://onco.cc/terms/mpn-driver-mutations/), [Performance status (ECOG, Karnofsky)](https://onco.cc/terms/performance-status/)
- drugs: [Fedratinib](https://onco.cc/drugs/fedratinib/), [Momelotinib](https://onco.cc/drugs/momelotinib/), [Pacritinib](https://onco.cc/drugs/pacritinib/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)
- cancers: [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)

---
JSON: https://onco.cc/api/v1/entities/dipss-mipss70.json